Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
"Wegovy Prior Authorization Resource Guide." PA criteria including BMI thresholds and documentation requirements
Participants receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of approximately 24% from baseline at 48 weeks a figure that, whilst encouraging, should be interpreted with caution as cross-trial comparisons with approved agents are not methodologically robust in the absence of head-to-head data
Mounjaro (tirzepatide) is a once-weekly subcutaneous injectable GLP-1/GIP receptor agonist approved by the FDA (U.S
20.0
US$ 20.71
US$ 20.71
US$ 28.02
